FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037432213> ?p ?o ?g. }

• W2037432213 endingPage "1492" @default.
• W2037432213 startingPage "1487" @default.
• W2037432213 abstract "Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan.We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment.After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (<140/90) was obtained in 10 of the 25 patients after switching to olmesartan. No adverse events occurred.Switching from other ARBs to olmesartan may be a promising therapeutic option in patients with resistant hypertension." @default.
• W2037432213 created "2016-06-24" @default.
• W2037432213 creator A5003477122 @default.
• W2037432213 creator A5019546205 @default.
• W2037432213 creator A5019738100 @default.
• W2037432213 creator A5020200536 @default.
• W2037432213 creator A5024729538 @default.
• W2037432213 creator A5030867158 @default.
• W2037432213 creator A5031034809 @default.
• W2037432213 creator A5038924268 @default.
• W2037432213 creator A5047704143 @default.
• W2037432213 creator A5050696605 @default.
• W2037432213 creator A5058549884 @default.
• W2037432213 creator A5064584338 @default.
• W2037432213 creator A5087593314 @default.
• W2037432213 creator A5089648713 @default.
• W2037432213 date "2015-07-01" @default.
• W2037432213 modified "2023-10-16" @default.
• W2037432213 title "Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan" @default.
• W2037432213 cites W1966000112 @default.
• W2037432213 cites W1970438162 @default.
• W2037432213 cites W1974985368 @default.
• W2037432213 cites W1979731702 @default.
• W2037432213 cites W1984973770 @default.
• W2037432213 cites W1988678286 @default.
• W2037432213 cites W1997148748 @default.
• W2037432213 cites W2009460506 @default.
• W2037432213 cites W2028414728 @default.
• W2037432213 cites W2047218153 @default.
• W2037432213 cites W2051143826 @default.
• W2037432213 cites W2057442959 @default.
• W2037432213 cites W2066971442 @default.
• W2037432213 cites W2075759443 @default.
• W2037432213 cites W2081718787 @default.
• W2037432213 cites W2082014484 @default.
• W2037432213 cites W2097196651 @default.
• W2037432213 cites W2101862793 @default.
• W2037432213 cites W2106962785 @default.
• W2037432213 cites W2109580224 @default.
• W2037432213 cites W2131554807 @default.
• W2037432213 cites W2144525223 @default.
• W2037432213 cites W2146798390 @default.
• W2037432213 cites W2152043519 @default.
• W2037432213 cites W2153553951 @default.
• W2037432213 cites W2155777324 @default.
• W2037432213 cites W2164449616 @default.
• W2037432213 cites W2166410990 @default.
• W2037432213 cites W2030475838 @default.
• W2037432213 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.015" @default.
• W2037432213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25891757" @default.
• W2037432213 hasPublicationYear "2015" @default.
• W2037432213 type Work @default.
• W2037432213 sameAs 2037432213 @default.
• W2037432213 citedByCount "7" @default.
• W2037432213 countsByYear W20374322132016 @default.
• W2037432213 countsByYear W20374322132017 @default.
• W2037432213 countsByYear W20374322132020 @default.
• W2037432213 countsByYear W20374322132021 @default.
• W2037432213 countsByYear W20374322132023 @default.
• W2037432213 crossrefType "journal-article" @default.
• W2037432213 hasAuthorship W2037432213A5003477122 @default.
• W2037432213 hasAuthorship W2037432213A5019546205 @default.
• W2037432213 hasAuthorship W2037432213A5019738100 @default.
• W2037432213 hasAuthorship W2037432213A5020200536 @default.
• W2037432213 hasAuthorship W2037432213A5024729538 @default.
• W2037432213 hasAuthorship W2037432213A5030867158 @default.
• W2037432213 hasAuthorship W2037432213A5031034809 @default.
• W2037432213 hasAuthorship W2037432213A5038924268 @default.
• W2037432213 hasAuthorship W2037432213A5047704143 @default.
• W2037432213 hasAuthorship W2037432213A5050696605 @default.
• W2037432213 hasAuthorship W2037432213A5058549884 @default.
• W2037432213 hasAuthorship W2037432213A5064584338 @default.
• W2037432213 hasAuthorship W2037432213A5087593314 @default.
• W2037432213 hasAuthorship W2037432213A5089648713 @default.
• W2037432213 hasConcept C126322002 @default.
• W2037432213 hasConcept C127413603 @default.
• W2037432213 hasConcept C134018914 @default.
• W2037432213 hasConcept C2776782570 @default.
• W2037432213 hasConcept C2777391703 @default.
• W2037432213 hasConcept C2779306644 @default.
• W2037432213 hasConcept C2779766728 @default.
• W2037432213 hasConcept C2780645631 @default.
• W2037432213 hasConcept C2908929049 @default.
• W2037432213 hasConcept C71924100 @default.
• W2037432213 hasConcept C78519656 @default.
• W2037432213 hasConcept C84393581 @default.
• W2037432213 hasConcept C98274493 @default.
• W2037432213 hasConceptScore W2037432213C126322002 @default.
• W2037432213 hasConceptScore W2037432213C127413603 @default.
• W2037432213 hasConceptScore W2037432213C134018914 @default.
• W2037432213 hasConceptScore W2037432213C2776782570 @default.
• W2037432213 hasConceptScore W2037432213C2777391703 @default.
• W2037432213 hasConceptScore W2037432213C2779306644 @default.
• W2037432213 hasConceptScore W2037432213C2779766728 @default.
• W2037432213 hasConceptScore W2037432213C2780645631 @default.
• W2037432213 hasConceptScore W2037432213C2908929049 @default.
• W2037432213 hasConceptScore W2037432213C71924100 @default.
• W2037432213 hasConceptScore W2037432213C78519656 @default.

• next